ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

UAV Unicorn Aim Vct Plc

91.50
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Unicorn Aim Vct Plc LSE:UAV London Ordinary Share GB00B1RTFN43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 91.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
88.00 95.00 91.50 91.50 91.50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Investors, Nec -5.67M -10.59M -0.0612 -14.95 158.18M
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 91.50 GBX

Unicorn Aim Vct (UAV) Latest News

Unicorn Aim Vct (UAV) Discussions and Chat

Unicorn Aim Vct Forums and Chat

Date Time Title Posts
27/3/202407:09Unicorn AIM VCT35

Add a New Thread

Unicorn Aim Vct (UAV) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Unicorn Aim Vct (UAV) Top Chat Posts

Top Posts
Posted at 17/4/2024 09:20 by Unicorn Aim Vct Daily Update
Unicorn Aim Vct Plc is listed in the Investors, Nec sector of the London Stock Exchange with ticker UAV. The last closing price for Unicorn Aim Vct was 91.50p.
Unicorn Aim Vct currently has 172,876,156 shares in issue. The market capitalisation of Unicorn Aim Vct is £158,181,683.
Unicorn Aim Vct has a price to earnings ratio (PE ratio) of -14.95.
This morning UAV shares opened at 91.50p
Posted at 13/2/2024 11:13 by toffeeman
Hi Bagpuss

Must stop meeting like this UAV SCE AGL!

Seriously though I am not a big earner but have bought UAV in the past to get the 30% tax rebate as I was at the LTA limit in my SIPP. Now however any spare dosh will go into my SIPP for a 40% rebate.
Posted at 09/2/2024 14:56 by topvest
Well I have subscribed to the offer today. I phoned-up to check following yesterday's surprise RNS and they are already £3m through the over-allotment facility. The offer only opened on the 8th...i.e. yesterday. It's very surprising that the share price is where it is, with this much demand. The whole offer may well be fully subscribed in a couple of days! It really does beg the question whether you should hold these VCT investments at bid or NAV in your portfolio.
Posted at 18/7/2022 09:16 by gbcol
It’s 3p & 32p.

“Following the sale of Interactive the Board has decided to distribute the entire realised gain by way of a Special Dividend of 32.0 pence per share alongside the interim dividend of 3.0 pence per share. This interim dividend and the special interim dividend will be paid on 11 August 2022 to Shareholders on the register on 15 July 2022. The shares will be quoted ex-dividend on 14 July 2022.”
Posted at 17/3/2022 14:12 by toffeeman
Just bought some of the new issue and with VCT relief my entry price is 138. Now need to leave it alone for 5 years :)
Posted at 08/12/2021 17:11 by sphere25
This is topical:

" Largest Detractors

Avacta Group (-GBP1.6 million) is a clinical stage biopharmaceutical specialist and a developer of diagnostics tools based on innovative and proprietary Affimer(R) and pre|CISION(TM) platforms. At the end of September, Avacta released interim results, which confirmed that the business continues to struggle to achieve widespread commercial adoption of its high quality Lateral Flow Tests. Financial results were therefore below original expectations and Avacta's share price has been under considerable pressure as a result.

Omega Diagnostics (-GBP1.2 million) is a business focused on providing specialist products to immunoassay, in-vitro diagnostics (IVD) market within the Health & Wellbeing sector. During the year, Omega released results for its financial year ended 31 March 2021. Because of the severe disruption caused by the pandemic, revenues did not grow as quickly as originally anticipated and the share price has suffered accordingly.

Abingdon Health (-GBP1.1 million) is a developer and manufacturer of high-quality rapid lateral flow tests. Unfortunately, throughout the year under review, Abingdon has been embroiled in a commercial dispute with the Department of Health and Social Care (DHSC), which translated into significantly lower than expected demand for its AbC-19 rapid antibody testing product. In addition, the DHSC continues to withhold payments due to Abingdon that amount to GBP6.7 million. This dispute remains unresolved, despite Abingdon's insistence that the contract was delivered to the DHSC on time, on budget and in full. As a result, Abingdon has failed to meet growth expectations in the twelve months since its initial listing on the FTSE AIM All-Share Index.

Genedrive (-GBP0.9 million) is a molecular diagnostics company that develops and commercialises low cost, rapid, versatile, and simple to use testing platforms for the diagnosis of infectious diseases. In its half yearly report, covering the six months to 31 December 2020, Genedrive was only able to generate nominal revenues as Covid-19 headwinds continued to impact its commercial operations. In September 2021, Genedrive raised GBP6 million in additional capital in order to fund the launch of a point-of-care (POC) antibiotic induced hearing loss (AIHL) test and complete the development of its molecular Covid-19 test. "

Should be interesting to see how they all fare next year!
Unicorn Aim Vct share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock